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New psychoactive substances have been rapidly growing in popularity in the drug market as non-illegal 
drugs. In the last few years, an increment has been reported on the use of synthetic alternatives to 
heroin, the synthetic opioids. Based on the information provided by the European Monitoring Centre for 
Drug and Drug Addiction, these synthetic opioids have been related to overdoses and deaths in Europe 
and North America. One of these opioids is the U-47700. A few months ago, U-47700 was scheduled 
in the U.S. and other countries, and other opioid derivatives have been appearing in order to replace 
it. One of these compounds is U-49900, an analog of U-47700. A white powder sample was obtained 
from an anonymous user in Spain. After an accurate characterization by gas chromatography-mass 
spectrometry, ultra-high performance liquid chromatography-high resolution mass spectrometry, 
nuclear magnetic resonance and single-crystal X-ray diffraction; and complemented by Fourier-
transformed infrared spectroscopy, ultraviolet and circular dichroism spectrophotometry, the drug 
sample was unequivocally identified as U-49900. The information provided will be useful for the Early 
Warning System and forensic laboratories for future identifications of the U-49900, as well as in 
tentative identifications of other related opioids.
In recent years, new psychoactive substances (NPS) have rapidly emerged in the drug market as a “legal” alterna-
tive to controlled drugs1, 2. The term “NPS” includes different compound families, such as synthetic cannabinoids, 
cathinones and opioids. In the last decade, an increase in the use of synthetic opioids as substance of abuse has 
been reported3, with the potential to pose serious risks to public health and safety. According to the EMCDDA 
European Drug Report 2016, synthetic opioids have been involved in overdose drug related deaths in some parts 
of Europe and North America, these compounds having been found in 82% of fatal overdoses4. For years, the 
diversity of available synthetic opioids in the grey market has been limited. Fentanyl analogues are limited by 
their high potency, making them unwieldy and dangerous to handle by users without proper safety procedures; 
thus, opioids such as MT-45 have been demonstrated to cause dangerous side effects5. Around 2012, a new class 
of synthetic opioids emerged. AH-7921 (Fig. 1), an opioid around 0.8 times as potent as morphine, developed at 
Allen & Hanburys Ltd in 19756, resurfaced on internet stores sold under the guise of being a research chemical 
“not for human consumption”. Effects described by users were similar to those of classical opioids: euphoria, 
sedation, pinned pupils, etc.7, and it saw relatively little popularity until its ban in 2013. Shortly after, an analogue 
of AH-7921 appeared on the market, U-47700 (Fig. 1), developed by Upjohn in 19788. In the Upjohn patent, 
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U-47700 is the compound most selective for the mu opioid receptor among all studied. It’s theorized to have a 
potency of around 7.5 times that of morphine, and binds to the mu opioid receptor (MOR) with a Ki (±SEM) 
of 0.91 nM (±0.11), to kappa opioid receptor (KOR) at 110 nM (±11), and poorly so to the delta opioid receptor 
(DOR) at 480 nM (±110). In comparison, morphine has Ki (±SEM) values at the MOR, KOR, and DOR of 0.213 
(±0.019), 27.9 (±2.7), and 111 (±14) nM, respectively.
U-47700’s presents a certain set of characteristics that make it particularly attractive to users, that until its 
appearance no other single substance had had. It is described by users as being more euphoric than fentanyl 
analogues, more potent than AH-7921, cheap, and widely available (at the time of writing this article)9. It is no 
surprising that it saw a surge in popularity, and has been the cause of at least 46 confirmed fatalities, as well as 88 
reports from forensic laboratories of U-47700 submissions in the U.S. alone10, as well as several fatalities in the 
rest of the globe11–16. With a common dose being six to eight milligrams, the cost per dose is no more than 0.32 
USD17. As a response to its growing popularity, the DEA placed U-47700 in emergency scheduling along with 
furanyl-fentanyl in November 11th, 201610.
The NPS market is quick to adapt however, and shortly before U-47700 was scheduled, U-51754, another 
synthetic opioid from the same Upjohn patent surfaced on the market. This substance is not as selective for KOR, 
and users describe it as being more dysphoric and dissociating than U-4770018. The most recent compound to 
surface, and a potential replacement for U-47700, is U-49900. Although both substance names bear a striking 
similarity, U-49900 does not appear on the same Upjohn patent as U-47700 or U-51754, and is in fact a com-
pletely novel substance that has not been described in literature until now. In this work, a sample (labelled as 
U-49900) was obtained by Energy Control from an anonymous Spanish user. After an exhaustive analysis by 
gas chromatography coupled to single-quadrupole mass spectrometry (GC-MS), ultra-high performance liquid 
chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS), nuclear magnetic resonance 
(NMR) and single-crystal X-ray diffraction, the compound was unequivocally characterized and thus, identi-
fied. Additionally, Fourier-transformed infrared (FTIR) spectroscopy, ultraviolet (UV) analysis, circular dichro-
ism (CD) and melting point range determination were performed in order to obtain a fully-characterization of 
the compound. This methodology has proved to be powerful for the identification of NPS, even for unknown 
substances19. The compound was confirmed to be the diethyl analogue of U-47700. In this work, we present 
the detailed analytical characterization of 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide, 
henceforth referred to as U-49900 (Fig. 1). Available information about its effects, price, availability, etc. has also 
been included.
Results
Analytical characterization of U-49900. Gas chromatography-quadrupole mass spectrometry. Firstly, 
the sample was analysed by GC-MS. A unique peak at 7.77 min was observed in the Total Ion Chromatogram 
(TIC), demonstrating the high purity of the sample (Fig. 2, top). The EI spectrum of this peak showed a high frag-
mentation, being the base peak the ion at m/z 112 (Fig. 2, bottom). This peak did not show the expected isotopic 
pattern produced by the putative presence of two chlorine atoms in the molecule. Additional fragment ions with 
an important intensity were observed at m/z 56, 84, 126, 144, 154 and 173. In this case, the ion at 173 presented 
the characteristic isotopic pattern corresponding to the presence of two chlorine atoms. Ions above m/z 200 were 
also observed, but with a lower intensity. Ions at m/z 284, 327 and 356 also presented the two-chlorine pattern. 
The molecular ion expected at m/z 356 was observed, but with a very low intensity, due to the high fragmentation 
obtained by EI. Despite all the information provided, this technique did not allow the unequivocal characteriza-
tion of the molecule and thus, additional techniques were used for the confirmation of the compound.
Liquid chromatography-high resolution mass spectrometry. UHPLC-HRMS analysis was performed in order to 
tentatively identify the compound based on its fragmentation. The soft ionization interface used allows the acqui-
sition of the protonated molecule in the LE spectrum. In Fig. 3 (left) the LE spectrum of the chromatographic 
peak at 6.72 min is showed. A unique peak at m/z 357.1500 was observed, corresponding the protonated mol-
ecule ([M + H]+) of the compound. The accurate-mass acquisition allowed the determination of the elemental 
composition of this m/z peak, being calculated as C18H27Cl2N2O+ with a mass error of 0.0 ppm. Other possible 
Figure 1. Chemical structure for AH-7921, U-47700 and expected structure for U-49900.
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elemental compositions were neglected due to the high mass error obtained. The determined elemental compo-
sition fitted with the theoretical elemental composition of U-49900. The isotopic pattern of the [M + H]+ showed 
an important peak at m/z 359, corresponding to the presence of two chlorine atoms in the molecule. The ratio 
between both peaks (65% approximately) was the expected for the ratio 35Cl2/35Cl37Cl. Similarly, the ratio between 
[M + H]+ and the peak at m/z 361 corresponding to the ratio between 35Cl2/37Cl2 was also observed. No signifi-
cant fragment ions were observed in the LE function.
The HE spectrum showed four important collision-induced fragment (CID) ions at m/z 284.0609, 203.9984, 
172.9560 and 81.0707 (Fig. 3, left). In order to evaluate if this fragment ions came from the protonated molecule, 
extracted ion chromatograms (EIC) were generated (Fig. 3, right). Ions at m/z 284, 204 and 173 showed the iso-
topic pattern corresponding to the presence of two chlorine atoms. Based on the expected structure of U-49900, 
these three ions would correspond to fragments which contain the dichlorophenyl group. This assumption was 
confirmed once their elemental composition was determined. Fragment at m/z 284 (C14H16Cl2NO+, 0.0 ppm) 
corresponds to the diethylamino loss; fragment at m/z 204 (C8H8Cl2NO+, 0.5 ppm) corresponds to the cyclohexyl 
loss from fragment at m/z 284; and fragment at m/z 173 (C7H3Cl2O+, −0.6 ppm) would be the methylamine loss 
of fragment 204. The other important fragment, at m/z 81 (C6H9+, 3.7 ppm), corresponds to the cyclohexyl ring, 
whose formation was already observed in the fragment at m/z 204 (a cyclohexyl ring loss from fragment m/z 284). 
All these fragments have been previously described in literature for the U-47700, and it was expected that some 
of them could also be observed for the U-4990012.
An accurate examination of the HE allowed the detection of five additional fragment ions, not previously 
observed due to their low intensity. The ions at m/z 185.9878 and 144.9614 also presented the isotopic pattern 
corresponding to the presence of two chlorine atoms. Fragment at m/z 186 (C8H6Cl2N+, 0.5 ppm) corresponds 
to the water loss from fragment at m/z 204. Thus, fragment at m/z 204 would present two different sequential 
fragmentations: a water loss (fragment at m/z 186) and a methylamine loss (m/z 173). The remaining dichlorin-
ated fragment at m/z 145 (C6H3Cl2+, 1.4 ppm) corresponds to the dichlorophenyl group. This fragment could be 
produced from fragment m/z 173 by a carbon monoxide loss, or from fragment m/z 186 by an azirine loss. Both 
fragments (at m/z 186 and 145) have also been described for the U-4770012.
Three minor fragments were observed at m/z 154.1597, 126.9951 and 110.0967. Fragments at m/z 154 
(C10H20N+, 0.6 ppm) and m/z 110 (C7H12N+, −2.7 ppm) correspond to the diethylcyclohexylamine group (which 
would come from [M + H]+) and the methylcyclohexylamine group (which would come from fragment at m/z 
284 by C-N amide bond fragmentation), respectively. Additionally, both fragments would be the precursors of 
fragment at m/z 81 (the cyclohexyl group), previously described. Regarding fragment at m/z 127 (C6H4ClO+, 0.0 
ppm), this fragment would correspond to a 2-chlorophenol group, but this structure is not present in the sup-
posed structure of U-49900. This fragment seems to be produced by an adduct formation with a neutral molecule 
present in the collision cell. The formation of fragment-adducts with small molecules in the collision cell has been 
recently described in literature20. According to literature, water adducts are the most commonly observed, due 
to water traces coming from the same instrument or CID gas impurities20. Based on this study, the fragment at 
m/z 127 would come from the dichlorophenyl fragment (m/z 145), experiencing a neutral HCl loss followed by 
Figure 2. GC-EI-MS analysis of the sample containing U-49900. Top: TIC of the sample analysis. Bottom: EI 
spectrum for the chromatographic peak at 7.77 min.
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a water addition, and subsequent formation of the 2-chlorophenol fragment. In this case, no information related 
with the U-47700 fragmentation was found in literature for fragments at m/z 154 (on the basis of the structure, 
this ion could not be present in U-47700), 127 and 110.
Finally, MS/MS experiments were performed in order to increase the confidence of the CID fragments 
acquired (spectra can be found in Supplementary Information, SI.1).
Once the compound was tentatively identified based on its accurate-mass fragmentation, a plausible fragmen-
tation pathway was proposed (Fig. 4). Nevertheless, a tentative identification was not enough to characterize the 
compound, thus additional spectroscopic techniques were applied for the identification and subsequent complete 
characterization of the U-49900.
Nuclear magnetic resonance. Different NMR experiments were performed in order to identify the compound. 
The first step was to perform 1H-NMR (Fig. 5, top) and COSY (Fig. 5, bottom) experiments (400 MHz, CDCl3). 
COSY are bidimensional NMR experiments (2D-NMR) which shows through-bond correlations between the 
hydrogens of the molecule. As the compound was tentatively identified by UHPLC-HRMS, most of the NMR 
signals were easily identified. For 1H-NMR, signals between δ = 7.5 and 8.0 ppm corresponded to the aromatic 
hydrogens, identifying each signal based on its multiplicity and chemical shift. Doublets corresponded to the 
hydrogens of carbon marked as 15 in Fig. 5 (C15) and C16 hydrogens. The C15 would correspond to the doublet 
with the highest chemical shift (δ = 7.89 ppm) due to the proximity of the chlorine atom; the C16 would corre-
spond to the other doublet (δ = 7.45 ppm). The third signal, a singlet, corresponded to C12 hydrogen (δ = 7.72 
ppm). COSY spectrum showed a correlation between C15 and C16 and no correlation with C12, as expected.
The signal at δ = 4.90 ppm would correspond to the C8 hydrogen based on the multiplicity and chemical shift. 
Similarly, the signal at δ = 3.39 ppm might correspond to the hydrogen in C3. A correlation between C3 and C8 
hydrogens was observed in COSY. The most intense signal in 1H-NMR was the singlet at δ = 2.98 ppm, produced 
by the methyl group named as C9 in Fig. 5, without correlations with other hydrogens.
The CH3 of both ethyl groups bonded to the cyclohexylamine were expected to be found as a triplet around 
δ = 1.5 ppm, with an integration corresponding to 6 hydrogens. Even so, the signal at δ = 1.46 ppm was a quadru-
plet with an integration of 7 hydrogens. Signals corresponding to protonated amines are expected to be between 
0.5 and 5 ppm, and it is possible that the observed quadruplet was produced by a triplet (corresponding to CH3) 
and a singlet (corresponding to NH+). In order to prove that, an additional 1H-NMR experiment was performed, 
using deuterated water as solvent (400 MHz, D2O). The use of deuterated water as solvent promotes protonatable 
groups to exchange deuterium from the solvent. These signals from 1H-NMR spectrum are therefore removed as 
Figure 3. UHPLC-HRMS MSE spectra of the U-49900. Right: Extracted ion chromatograms (EIC) (0.02 Da 
mass window) for protonated molecule in LE function, and fragment ions in HE function. Left: LE (bottom) 
and HE (top) spectra of U-49900.
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deuterium does not produce resonance in 1H-NMR. The resulting signal was a triplet whose integration corre-
sponded to 6 hydrogens, therefore confirming our hypothesis. 1H-NMR spectra acquired using CDCl3 and D2O 
comparison can be found in Supplementary Information SI.2. So, the signal at δ = 1.46 ppm was assigned to the 
hydrogens of C1 and the proton of the amine (Fig. 5).
Signals at δ = 2.75 and 3.70 ppm would correspond to the CH2 of the ethyl groups (C2), but producing differ-
ent chemical shifts. This would indicate that the ethyl groups presented a different electronic surrounding. The 
protonation of the amine could produce an intramolecular hydrogen bond between this proton and the oxygen 
atom or the nitrogen atom of the amide group. The formation of this bond would hamper the free rotation of 
the N-cyclohexyl bond, producing the diastereotopicity of the C2 hydrogens. Once the signals produced by C2 
hydrogens were identified, the correlation with C1 hydrogens was confirmed after performing an accurate study 
of the COSY spectrum. Finally, low-intense signals between δ = 0 and 2 ppm corresponded to CH2 cyclohexyl 
hydrogens (C4-C7), as is explained in the 13C-NMR and HSQC study.
The second step was to perform 13C-NMR (Fig. 6, top) and HSQC (Fig. 6, bottom) experiments (400 MHz, 
CDCl3). HSQC is a 2D-NMR experiment which establishes the through-bond correlation between the carbon 
atoms and their bonded hydrogens. HSQC spectra work with a colour code: CH3 and CH groups are represented 
in one colour, while CH2 is represented in another one. In this case, in the HSQC spectrum of U-49900 CH3/
CH are represented in red-yellow spots, while CH2 is represented in blue spots (Fig. 6, bottom). Most 13C-NMR 
signals were assigned based on the assignation previously performed in 1H-NMR and looking for the correlation 
between carbon and hydrogen signals in HSQC. Quaternary carbon atoms, which have no hydrogens and thus 
no signal in 1H-NMR, were identified based on the chemical shift. Signal at δ = 171.46 ppm corresponded to the 
carbon atom of the amide group (C10). The three signals in the aromatic region (between δ = 100 and 140 ppm) 
which did not have correlation with 1H-NMR signals corresponded to the functionalized carbon atoms of the 
benzene ring. Signals at δ = 133.97 and 135.80 ppm were assigned to the carbons bonded to chlorine atoms (C13 
and C14), while signal at δ = 132.37 ppm corresponded to C11.
An accurate analysis of the HSQC spectrum confirmed the previously explained supposition: the hydrogens 
of C2 are diastereotopic. 13C-NMR spectrum showed a slight change in the chemical shift of both C2 carbons, 
probably due to the proximity of one of them to the nitrogen atom of the amide group. HSQC also showed the 
correlation between 13C-NMR signals corresponding to C2 carbon, and the two observed signals in 1H-NMR 
related previously to C2 hydrogens, reinforcing the supposition of the amine protonation. Finally, signals corre-
sponding to CH2 of the cyclohexyl (signals between δ = 0 and 2 ppm in 1H-NMR) presented diastereotopicity. 
This was observed in HSQC spectrum as a double 1H-NMR signal corresponding to a single 13C-NMR signal. In 
other words, there were two different hydrogens in each carbon atom of the cyclohexane. This double signal was 
easy to justify, as the hydrogens of a CH2 in a cyclohexane can present two different orientations: axial and equato-
rial. The different orientation of the hydrogens produces diastereotopicity in hydrogens theoretically equivalents.
The combination of COSY and HSQC spectra allowed a complete NMR characterization of the compound, 
increasing the confidence on the tentative identification of the structure of U-49900. Table 1 and Fig. 7 show the 
assignation of 1H and 13C-NMR signals once stablished the correlation between atoms and signals.
In order to increase the confidence on the NMR characterization, a HMBC experiment was performed in 
order to establish correlations over 2 heteronuclear bonds (SI.3).
The combination of UHPLC-HRMS and NMR experiments allow the complete identification of the com-
pound. Nevertheless, an additional analytical technique was applied in order to unequivocally confirm the iden-
tity of U-49900.
Figure 4. Proposed CID fragmentation pathway for the U-49900.
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Single-crystal X-ray diffraction. The unambiguous confirmation of the structure of U-49900 was performed by 
single-crystal X-ray diffraction analysis. Crystal evaluation and diffraction data were collected by using an Agilent 
Supernova diffractometer equipped with an Atlas CCD detector. No instrument or crystal instabilities were 
observed during data collection. Structure of U-49900 was solved by charge flipping methods using Superflip and 
refined by the full-matrix method on the basis of F2 with the program SHELXL-2013, using the OLEX software 
package21–23. Absorption correction based on the multiscan method was applied24. The graphic was performed 
with the Diamond visual crystal structure information system software25. Crystal data and structure refinement 
information are summarized in Table 2. All non-hydrogen atoms were refined anisotropically and the H atoms 
were positioned geometrically, assigned isotropic thermal parameters and allowed to ride on their respective 
parent carbon atoms.
U-49900 structure was refined in the triclinic space group P-1 with cell dimensions of a = 73.0052(13) Å, 
b = 8.14672(13) Å, c = 18.8525(3) Å and α = 78.9257(14)°, β = 82.3114(14)° and γ = 66.9588(16)°. Figure 8 shows 
Figure 5. Top: 1H-NMR spectrum for U-49900 with signal assignation based on compound structure. Bottom: 
COSY spectrum of U-49900.
www.nature.com/scientificreports/
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the ORTEP representation of the structure with the atom-numbering scheme. Protonation of the diethylamine 
group observed after performing NMR analyses was confirmed in the solid structure. This protonation produces 
the stereotopicity of the ethyl groups bonded to the nitrogen atom. However, the centrosymmetric P-1 space 
group evidences the racemic nature of the compound. Additionally, X-ray analysis demonstrated the high purity 
degree of this new substance and the high similarity to U-47700, and allowed the unequivocally identification of 
U-49900.
All data regarding single-crystal X-ray crystallography and structure refinement were included in the 
Cambridge Crystallographic Data Centre (CCDC). This information can be found free of charge in the CCDC 
1546594 file available at www.ccdc.cam.ac.uk/data_request/cif.
Additional characterization. FTIR and UV analyses were performed in order to obtain additional informa-
tion about the compound. These spectra can be found in Supplementary Information (SI.4 and SI.5, respec-
tively). Moreover, the melting point range was determined and established to be between 169–171 °C. Finally, 
Figure 6. Top: 13C-NMR spectrum for U-49900. Bottom: HSQC spectrum of U-49900.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 6338 | DOI:10.1038/s41598-017-06778-9
CD measurements were carried out to check the optical activity of U-49900. No Cotton effects were observed, 
confirming the racemic nature of this new drug.
Psychoactive effects and availability of the drug as described by consumers. U-49900 is first 
mentioned online on November 2nd, 2016 on Bluelight, a popular drug forum, by a user announcing its availabil-
ity and querying other users about possible effects. Users expressed concerns about its possible health hazards, as 
it is a close analogue to U-47700, which has been linked to damaged veins, damage to nasal and rectal passages, 
violent withdrawals, and other concerning effects26, 27. Most forum threads reference the same post made by the 
anonymous user28. In the post, the user reports concerning side effects like pain upon insufflation, loss of taste, 
loss of smell, neurologic pain on the left side of the body, loss of the sense of touch, and a foam-like discharge 
from the lungs.
Reports of effects are few and far between, as most users that inquire about effects are linked to the aforemen-
tioned post and subsequently refrain from consuming the substance29. A user on the Swedish forum Flashback 
reports classic opioid effects from a dose of 50 mg intravenous30. Users on the same Swedish forum have tried 
U-49900 at doses of 5–10 milligrams and report no activity, whereas U-47700 is active in those amounts.
Discussion
In this work, the combination of different analytical techniques has allowed the unequivocal characterization of 
the novel opioid derivative U-49900. The use of HRMS, NMR and single-crystal X-ray diffraction has proved 
to be a powerful approach for the identification of NPS when reference standards are not available. Moreover, 
information obtained by GC-MS, FTIR and UV are also provided, in order to facilitate the identification of this 
compound in forensic laboratories with routine equipment. Although the present methodology could be used for 
the elucidation of most of organic compounds, it is especially useful for monitoring NPS due to the continuous 
1H-NMR signal assignment 13C-NMR signal assignment
Hydrogen δ (ppm) Multiplicity Carbon δ (ppm)
1 + NH+ 1.47 Quadruplet 1 10.25–10.15
2 2.75–3.70 Multiplet 2 45.75–46.49
3 3.39 Triplet 3 58.27
4 1.51–2.01 — 4 23.81
5 1.28–1.86 — 5 24.64
6 1.44–1.91 — 6 24.46
7 1.68–1.86 — 7 29.91
8 4.90 Triplet 8 52.04
9 2.98 Singlet 9 33.24
10 — — 10 171.46
11 — — 11 132.37
12 7.72 Singlet 12 129.54
13 — — 13 135.80
14 — — 14 133.97
15 7.89 Doublet 15 127.79
16 7.45 Doublet 16 130.51
Table 1. 1H and 13C-NMR signal assignment. δ: chemical shift.
Figure 7. 1H and 13C-NMR signal assignment.
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Parameter Data
Empirical formula C18H26Cl2N2O·HCl·H2O
Formula weight 411.78
Temperature (K) 200.0 (10)
Crystal system Triclinic
Space group P-1
Unit cell dimensions
  a, Å 7.30052 (13)
  b, Å 8.14672 (13)
  c, Å 18.8525 (3)
  α, ° 78.9257 (14)
  β, ° 82.3114 (14)
  γ, ° 66.9588 (16)
  Volume (Å3) 1010.46 (3)
  Z 2
  ρcalc (mg/mm3) 1.353
  Absorption coefficient µ (mm−1) 4.218
  F(000) 436.0
  Crystal size (mm3) 0.174 × 0.12 × 0.095
  Radiation CuKα (λ = 1.54184)
  2Θ range for data collection (°) 9.58 to 134.152
  Index ranges −8 ≤ h ≤ 8
−9 ≤ k ≤ 9
−22 ≤ l ≤ 22
Reflections collected 27700
Independent reflections 3616 [Rint = 0.0321, Rsigma = 0.0153]
Absorption correction Multi-scan
Refinement method Full-matrix least-squares on F2
Data/restrains/parameters 3616/0/232
Goodness of fit on F2 1.040
Final R indices [I > 2σ(I)] R1 = 0.0288
wR2 = 0.0754
R indices (all data) R1 = 0.0320
wR2 = 0.0784
Largest difference in peak/hole 
(e·A−3) 0.30/−0.23
Table 2. Crystallographic data for U-49900.
Figure 8. ORTEP representation (ellipsoids at the 50% probability level) of the U-49900 chloride protonated 
salt with the atom-numbering scheme. Selected bond lengths [Å]: N1-C7 1.356(9); N1-C8 1.466(9); N1-C9 
1.479(9); N2-C14 1.528(9); N2-C15 1.512(9); C3-Cl1 1.732(9); C7-O1 1.234(9); C7-C6 1.502(11). Hydrogen 
atoms, except that of the protonated amine, have been omitted for clarity.
www.nature.com/scientificreports/
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on-going of these substances. This fact is the main handicap for obtaining reference standards, making the com-
bination of powerful techniques necessary for unequivocal identification of NPS.
Although U-49900 is reported to be active, the doses taken are much larger than U-47700. Less than a year 
has passed since its first appearance on fora, but users’ experiences seem to indicate that U-49900 is yet another 
lackluster successor to U-4770029.
It is interesting to note that users of fora dedicated to NPS and other drug discussion seem to have a 
self-regulating system for novel compounds. Although these users are treading unknown territory, they are quick 
to share effects and side effects of NPS, and when such effects are concerning, they promptly share it with others 
and tend to steer clear of the substances discussed. One notable example is MT-45, a synthetic opioid developed 
in the 1970s by Dainippon Pharmaceutical Co31, which surfaced on internet shops late 20125, 32, and has been 
involved in several non-fatal as well as fatal intoxications around the world. Users were quick to realize that 
among various side effects, MT-45 caused hearing loss and unconsciousness, and popularity dwindled well before 
its regulation in some European countries (like the UK and Czech Republic33) around 2015. It’s possible that this 
is due to the negative side effects being widely reported on and shared across NPS-focused fora. With U-49900 a 
similar trend appears to be taking place, as reports of use have been slow to surface, and most users that inquire 
about it are warned about potential side effects and resolve to stay away from the substance.
Possibly one of the most curious aspects of U-49900 is that, aside from bearing a striking structural simi-
larity to U-47700, the name itself is a clear reference to this compound. It is, in fact, quite peculiar that the first 
appearance of this compound comes from a Chinese retailer34, and not from old studies or patents, as tends to 
be the case for most NPS. U-49900 is likely a deliberate attempt to find a similar compound to U-47700, and 
demonstrates at least a rudimentary grasp of pharmacology, seeing as the modification is minor, and in theory 
the compound should retain similar activity to its parent compound. A similar case is methoxetamine, an NPS 
structurally similar to ketamine and other arylcyclohexylamines, which surfaced on online shops before being 
mentioned on any scientific literature. There is an enigmatic interview with a British biochemist that went by the 
pseudonym “M”35 who claimed to have had a hand in the ideation and synthesis of this compound36. This suggests 
that for some NPS, the research and development stage is conducted in countries that have a market for NPS, and 
their production is then outsourced to Chinese laboratories. It is plausible that this is also the case for U-49900, 
and that there is a development process that took place in a European or North American country.
So far, there are no reported deaths related to U-49900, but at least 46 deaths were reported in the US alone 
with U-47700 being involved. Although this may appear to be a high figure, it pales in comparison to illicit fen-
tanyl and its analogues, perhaps the closest contenders to the U-XXXXX family for use by opioid users, which 
have been involved in hundreds of deaths in the US alone37–39. It is clear that U-47700 is a harmful substance, 
with a much lower safety margin than other opioids or opiates, but the fact that the dosage is more manageable 
than fentanyl analogues, and the ratio of euphoric effects to respiratory depression suggests that users may be less 
prone to overdosing in the quest for the effects they are accustomed to with classical opiates.
This is especially important in US, where there is an important problem with opioid and opiate abuse. Users 
tend to start with pharmaceutical derivatives, such as codeine or tramadol, which are perceived as less harmful 
and their use is less stigmatized40. Some eventually migrate to more potent and euphoric derivatives, such as oxy-
codone or oxymorphone. When a dependence develops and the cost of the habit becomes prohibitive, some users 
may transition to illegal opioids and opiates, such as heroin, fentanyl analogues and/or novel opioid derivatives, 
such as non-pharmaceutical fentanyl, U-47700, or U-49900. These compounds tend to have lower safety margins 
than the more studied classical opiates. It is therefore important to evaluate the repercussions of scheduling novel 
opioids without contemplating future derivatives. It seems that scheduling these compounds as they surface has 
not been effective at curbing novel opioid abuse. A similar phenomenon was observed for synthetic cannabinoids, 
where the first generation (JWH-018, etc.) were prone to seizures, causing dependence, and other complications, 
but the latest generation, the result of several waves of prohibition, are more potent, more prone to causing com-
plications, and have been involved in a striking amount of deaths41–43.
After the unequivocal identification of U-49900, metabolism and toxicological studies would be needed to 
get comprehensive information on this drug. The study of metabolic pathways of NPS is crucial for establishing 
the consumption biomarkers of these substances in urine for their monitoring in intoxication and overdoses 
cases44. However, obtaining urine or serum from intoxication cases is troublesome, as the source of the intox-
ication is commonly unknown. In the case of U-47700, a possible metabolism pathway has been proposed in 
literature14 (Supplementary Information SI.6), including 10 tentative metabolites. The major metabolites were the 
N-desmethyl and N,N-bisdesmetyl derivatives, which were found in a urine sample from a subject after U-47700 
overdose.
In view of the difficulties of performing metabolism studies in humans, the in vivo approach using animals 
plays an important role. The use of different animal models (mice or rats) has demonstrated its efficiency for 
obtaining potential consumption markers of NPS in human urine samples45, 46. So, future research will be focused 
on metabolites identification of U-49900 using in vivo models (similarly to the analogue U-47700). Information 
provided on these or similar studies will be useful for monitoring this compound in consumers and in possible 
intoxication cases.
As a final note, a new opioid analogue related to U-47700 and identified as 3,4-dichloro-N-(2-(diethylamino)
cyclohexyl)-N-methylbenzamide (also known as U-49900) has been identified and characterized in a drug sample 
from Spain. Characterization of the compound consisted of GC-MS analysis, UHPLC-HRMS, NMR, 2D-NMR 
analyses and single-crystal X-ray diffraction, unequivocally confirming its chemical structure. Additionally, 
FTIR, UV and CD spectra, as well as melting point range were measured in order to obtain a complete charac-
terization of U-49900. The information reported in this work about this new opioid analogue will be useful to 
enhance the Early Warning Systems and for future toxicological studies.
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It seems that demand for novel opioids does not decrease when a compound is scheduled, and if the supply 
for a certain substance dwindles, users are bound to seek an alternative. AH-7291 was dangerous, U-47700 has 
been proven to be more widespread and even more problematic, and the newest generation of derivatives, such 
as U-49900 and U-51754 do not seem to be of less concern. While it is clear that a solution needs to be found, 
perhaps quickly and systematically scheduling new compounds as they gain popularity can be complemented 
with other prevention measures in response to the growing problem of NPS abuse.
Future work on U-49900 will be focused on the metabolic pathway of this opioid in urine samples from 
in vivo experiments, as well as on the proposal of potential consumption markers. These studies will be useful for 
monitoring U-49900 in consumers and in suspicious intoxication cases.
Methods
Drug sample. The suspect sample (consisting on white powder) was submitted by an anonymous user to 
Energy Control for its analysis. Additional information about Energy Control can be seen elsewhere47.
Reagents and chemicals. For GC-MS analysis, HPLC-grade methanol (MeOH) was purchased from Panreac 
(Panreac, Barcelona, Spain). For UHPLC-HRMS analysis, HPLC-grade water was obtained by purifying dem-
ineralized water using a Milli-Q system from Millipore (Bedford, MA, USA). HPLC-grade methanol (MeOH), 
HPLC-grade acetonitrile (ACN), formic acid (HCOOH), acetone, and sodium hydroxide (NaOH) were acquired 
from Scharlau (Scharlab, Barcelona, Spain). Leucine enkephalin was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). For NMR analysis, deuterated chloroform (CDCl3) and deuterated waters (D2O) were purchased 
from Sigma-Aldrich. For single-crystal X-ray analysis, GC ultra-trace analysis grade dichloromethane (stabilized 
with ethanol) and GC ultra-trace analysis grade n-hexane were purchased from Scharlau. For FTIR analysis 
potassium bromide (KBr) was purchased from Scharlau. For UV and CD analyses, ACN was purchased from 
Scharlau.
Sample treatment. For GC-MS analysis, 10 mg of bulk sample were sonication-assisted dissolved with 10 mL 
of MeOH during 15 min. The extract was then centrifuged to remove insoluble material and afterwards directly 
injected into GC-MS system.
For UHPLC-HRMS analysis, 10 mg of sample were extracted with 1 mL of acetone in an ultrasonic bath for 
15 min, following the sample treatment described in literature48, 49. After centrifugation, the supernatant was 
ten thousand-fold diluted with HPLC-grade water, and 20 µL of the extract were injected in the UHPLC-HRMS 
system.
For NMR analysis, approximately 15 mg of sample were dissolved in 0.6 mL of CDCl3. Additionally, 15 mg of 
sample were dissolved in 0.6 mL of D2O in order to obtain a 1H-NMR spectrum without the protonated amine 
signal.
The recrystallization was performed by dissolving 10 mg of sample in 1 mL of dichloromethane in a glass 
vial, and dropwise addition of n-hexane, taking care to avoid mixing both solvents. The process was performed 
over-night, by diffusion of n-hexane in dichloromethane and thus, precipitating the compound and crystallizing 
it. Needle-shaped crystals were obtained and used for X-ray diffraction.
For FTIR analysis, the sample was mixed with KBr in a ratio 5:95 and homogenized in an agate mortar. Finally, 
the mixture was compressed under a pressure of 5000 kg/cm2.
For UV and CD analyses, the compound was dissolved in ACN at 10−4 M, preparing the appropriate volume 
of dissolution.
Instrumentation. For GC-MS analysis, an Agilent 7890B gas chromatograph was coupled to a 5977 A quad-
rupole mass spectrometer detector (Agilent Technologies, Santa Clara, CA, USA) using an electron ionization 
(EI) interface. The gas chromatograph was fitted with a G4513A auto-sampler injector (Agilent). Insert liners 
packed with silanized glass wool were used, and the injector and the interface were operated at 280 °C. 1 µL of 
sample was injected in split mode, with a split ratio 1:10, into a 30 m 0.25 mm i.d., 0.25 μm film thickness 5% 
phenylmethylsilicone column (HP-5MS, Agilent). Helium was used as carrier gas at a flow rate of 1 mL/min. The 
oven temperature was initially maintained at 90 °C for 2 min and programmed to reach 320 °C at 20 °C per min. 
It was finally maintained at 320 °C for 9.5 min (total run time was 21.5 min). The mass spectrometer was operated 
in electronic ionization mode at 70 eV. MS system worked in SCAN acquisition mode, acquiring from m/z 40 to 
400 Da. Analytical data were acquired and processed using MassHunter B.06.00 (Agilent) operation software.
UHPLC-HRMS analysis was performed using an ACQUITY UPLC ultra-high performance liquid chro-
matography (UHPLC) system (Waters, Mildford, MA, USA) coupled to a XEVO G2 QTOF hybrid quadrupole 
time-of-flight (QTOF) mass spectrometer (Waters Micromass, Manchester, UK) with an orthogonal Z-spray elec-
trospray ionization (ESI) interface operating in positive ionization mode. The chromatographic separation was 
performed using a CORTECS C18 (Waters) 2.7 µm particle size analytical column 100 × 2.1 mm at a flow rate of 
0.3 mL/min. The column temperature was set to 40 °C. The mobile phases used were H2O with 0.01% HCOOH 
(A) and MeOH with 0.01% HCOOH (B). The mobile phase gradient was performed as follows: 10% of B at 
0 min, 90% of B at 14 min linearly increased, 90% of B at 16 min, and finally 10% B at 18 min in order to return to 
initial conditions. The injection volume was 10 µL. Nitrogen (Praxair, Valencia, Spain) was used as desolvation 
and nebulizing gas. The desolvation gas flow was set at 1000 L/h. The TOF resolution was ~20000 at FWHM at 
m/z 556. The range acquired by the MS system was from m/z 50 to 1000. A capillary voltage of 0.7 kV and a cone 
voltage of 20 V were used during all the chromatographic run. Argon 99.995% (Praxair, Valencia, Spain) was 
used as a collision gas. The interface temperature was set to 650 °C and the source temperature to 120 °C. For MSE 
experiments, two acquisition functions with different collision energy were created. The low energy function 
(LE) used a collision energy of 4 eV in order to obtain information about the protonated molecule and adducts 
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(if present), while the high energy function (HE) applied a collision energy ramp from 15 to 40 eV, in order to 
promote fragmentation of the compounds48. Calibration of the mass-axis was performed daily from m/z 50 to 
1000 using a 1:1 mixture of 0.05 M NaOH:5% HCOOH, diluted 1:25 with ACN:H2O 80:20 mixture. For accurate 
mass measurement, a 2 µg/mL leucine enkephalin solution in ACN:H2O 50:50 with 0.1% HCOOH was used as 
lock-mass, pumped at a flow rate of 20 µL/min. The leucine enkephalin protonated molecule (m/z 556.2771) was 
used for recalibrating the mass axis and ensure an accurate mass during all the chromatographic run. MS data 
were acquired in centroid mode using MassLynx data station operation software, version 4.1 (Waters).
NMR analyses were performed using a Bruker Ascend 400 MHz spectrometer equipped with a SampleCase 
autosampler (Bruker, Etlingen, Germany), performing data acquisition at 303 K using CDCl3. The residual sol-
vents signals at δ = 7.24 ppm for 1H (CHCl3) and at δ = 77.23 ppm for 13C (CDCl3) were used as internal refer-
ences. Characterization of the compound was performed using 5 gradient-enhanced experiments: 1H-NMR, 
13C-NMR, correlated spectroscopy (COSY), heteronuclear single quantum coherence (HSQC), and heteronu-
clear multiple bond correlation (HMBC). NMR experiment data were collected using the Bruker Icon NMR 
5.0.5 software (Bruker). MestreNova program was used for raw data processing (Mestrelab Research, Santiago de 
Compostela, Spain).
For single-crystal X-ray diffraction crystallography, an Agilent SuperNova diffractometer (Agilent 
Technologies) was used. The diffractometer was equipped with an Atlas CCD detector (Agilent Technologies), 
and CuKα radiation (λ = 1.54184 Å) was used. Sample was kept at 199.95 K during data collection. Experimental 
data was acquired using the SHELXS-2013 software (Yale University, New Haven, CT, USA), using the OLEX 
software package (Olex AS, Trondheim, Norway).
For FTIR analysis, a Jasco FT/IR-6200 FTIR spectrometer (Jasco Inc., Easton, MD, USA) was used. Data 
acquisition was performed at 23 °C between 4000 and 400 cm−1, with a resolution of 4 cm−1 and performing 32 
acquisitions.
For UV and CD analyses, a Jasco J-810 spectrophotometer (Jasco Inc., Easton, MD, USA) was used. Data 
acquisition was performed at 23 °C between 200 and 400 nm, with a resolution of 1 nm, a scanning speed of 
100 nm/min and performing 2 acquisitions.
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